NYSE · LLY
Eli Lilly and Company
$1,416.35+$42.65 (+3.1%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.3% below the high.
Loading market information…
NASDAQ · CV · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CapsoVision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CapsoVision, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CapsoVision, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 9, 2025 | -$1.31-1,090.91% vs estimate | $2.79M-14.02% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $9.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,416.35+$42.65 (+3.1%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.3% below the high.
$273.18-$2.02 (-0.73%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
$294.87+$4.08 (+1.4%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.3% below the high.
$149.52+$3.19 (+2.18%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
$406.90-$4.01 (-0.98%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.85% below the high.
$697.00-$12.18 (-1.72%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$466.01+$5.28 (+1.15%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.03% below the high.
$170.74+$5.13 (+3.1%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.8% below the high.
